Abeona Therapeutics vs Aquestive Therapeutics
ABEO and AQST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABEO and AQST compare
Aquestive Therapeutics is the larger company, worth 3.5 times as much as Abeona Therapeutics ($491M against $138M).
Abeona Therapeutics keeps more of each dollar of sales as profit, with a net margin of −160% compared with −162% at Aquestive Therapeutics.
Abeona Therapeutics scores higher on the StockData Score (8 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABEO | AQST |
|---|---|---|
| Size and price | ||
| Market cap | $138M | $491M |
| Share price | $2.42 | $3.91 |
| Change, 1 year | −51.0% | −29.9% |
| Change, 5 years | −86.9% | −34.5% |
| Beta (5Y) | 1.30 | 1.45 |
| Employees | 226 | 147 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.5× (better) | 10.0× |
| P/B | 1.1× | – |
| FCF yield | −47.9% | −8.3% (better) |
| Fair value | $3.99 | – |
| Margin of safety | 39.4% | – |
| Growth | ||
| Revenue growth (TTM) | – | 12.5% |
| Revenue growth, 5Y average | −10.3% | −0.58% (better) |
| Net income growth (TTM) | −176% | – |
| Profitability | ||
| Gross margin | 65.1% | 65.3% (better) |
| Operating margin | −186% | −114% (better) |
| Net margin | −160% (better) | −162% |
| FCF margin | −170% | −83.3% (better) |
| Return on equity | −42.1% | – |
| Financial health | ||
| Debt / equity | 0.09 | – |
| Interest coverage | −24.5× | −5.4× (better) |
| Current ratio | 5.69 | 6.12 (better) |
| Altman Z-score | −4.84 | −4.49 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.9% | 57.4% |
| Held by insiders | 12.3% | 3.2% |
| Insider net buying, 12 months | −$3.5M | −$2.3M (better) |
| Short interest, % of float | 33.6% | 24.1% |
Go deeper
- ABEO stock overview
- ABEO income statement
- ABEO valuation and score
- AQST stock overview
- AQST income statement
- AQST valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.